Life expectancy has been increasing in patients with Duchenne muscular dystrophy (DMD), according to an analysis of some 40 years of data, spanning births from before 1970 to the late 2000s. In fact, the median life expectancy of males with DMD born in the late 1990s advanced to more than…
News
A potentially pivotal Phase 3 clinical trial called HOPE-3, which will test the effectiveness of the experimental cell therapy CAP-1002 as a treatment for Duchenne muscular dystrophy (DMD), is expected to launch soon. Capricor Therapeutics, the company developing CAP-1002, announced that the U.S. Food and Drug Administration…
A protein called GCN5 is vital for normal muscle health and helps to coordinate the expression of several important muscle proteins, including dystrophin, according to a study done in mice. The results suggest that targeting GCN5 may be a useful therapeutic avenue in diseases of the muscles, such as…
The U.S. Food and Drug Administration (FDA) has placed a hold on Dyne Therapeutics’ application to launch a clinical trial evaluating DYNE-251, an experimental exon-skipping therapy for Duchenne muscular dystrophy (DMD). Dyne now hopes to have that Phase 1/2 trial underway by June, the company said in a …
Cognitive problems seen in some Duchenne muscular dystrophy (DMD) patients may be associated with a shift toward the amyloidogenic pathway in memory-specific brain regions, according to a study in mouse models of the disease. The amyloidogenic pathway is a signaling cascade that leads to the formation of beta-amyloid, the…
The U.S. Food and Drug Administration (FDA) has approved Regenxbio’s request to launch a Phase 1/2 clinical trial in the U.S. evaluating the safety and efficacy of RGX-202, its experimental gene therapy for Duchenne muscular dystrophy (DMD). The study, called AFFINITY DUCHENNE and anticipated to start in…
Children with Duchenne muscular dystrophy (DMD) who had been given a placebo in a clinical trial experienced a marked improvement in motor abilities after being treated with Sarepta Therapeutics‘ experimental gene therapy SRP-9001, new top-line data show. “We are delighted to report positive results for Part 2 of…
The experimental oral therapy EDG-5506 is generally safe and results in rapid and profound reductions in the levels of muscle damage biomarkers in men with Becker muscular dystrophy (BMD), top-line data from a Phase 1b clinical trial show. “We believe the magnitude of reduction in multiple key biomarkers of muscle…
Muscular Dystrophy News Today brought you daily coverage of the latest scientific findings, treatment developments, and clinical trials related to muscular dystrophy (MD) throughout 2021. We look forward to reporting more news to patients, family members, and caregivers dealing with MD during 2022. Here are the top 10 most-read articles of…
Genetic medicines company Gennao Bio will use a $1 million CureDuchenne Ventures investment to help expand its gene monoclonal antibody (GMAB) platform technology, which is now applied to rare muscle disorders, including Duchenne muscular dystrophy (DMD). The initial focus of the nonviral delivery system Gennao Bio is…
Recent Posts
- When it comes to accessibility, even the best-laid plans can go awry
- ‘Heart-on-a-chip’ project to help researchers study BMD, DMD
- Guest Voice: After diagnosis, focusing on what we can do
- Remembering a dear friend, who taught me about leaving a legacy
- What MDA Summer Camp taught me about why we show up